Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.34 HKD | +3.03% | +6.25% | -65.66% |
Sales 2024 * | 130M 17.96M 140M | Sales 2025 * | 150M 20.72M 162M | Capitalization | 134M 18.48M 144M |
---|---|---|---|---|---|
Net income 2024 * | -250M -34.54M -270M | Net income 2025 * | -324M -44.76M -350M | EV / Sales 2024 * | 1.03 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.89 x |
P/E ratio 2024 * |
-0.53
x | P/E ratio 2025 * |
-0.41
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.98% |
Latest transcript on CANbridge Pharmaceuticals Inc.
1 day | +3.03% | ||
1 week | +6.25% | ||
1 month | -24.44% | ||
3 months | -17.07% | ||
6 months | -64.95% | ||
Current year | -65.66% |
Managers | Title | Age | Since |
---|---|---|---|
James Xue
CEO | Chief Executive Officer | 55 | 18-01-29 |
Glenn Hassan
DFI | Director of Finance/CFO | 46 | 19-04-01 |
Gerald Cox
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Hu
BRD | Director/Board Member | 61 | 22-07-04 |
James Geraghty
BRD | Director/Board Member | 69 | 18-07-17 |
Peng Kuan Chan
BRD | Director/Board Member | 60 | 21-06-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 0.34 | +3.03% | 43 000 |
24-06-03 | 0.33 | -2.94% | 25,000 |
24-05-31 | 0.34 | -1.45% | 92,000 |
24-05-30 | 0.345 | +7.81% | 44,000 |
24-05-29 | 0.32 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., June 04, 2024 at 04:08 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-65.66% | 17.93M | |
+14.26% | 9.15B | |
-13.94% | 4.9B | |
+48.58% | 4.46B | |
+14.10% | 4.09B | |
+19.66% | 2.49B | |
-25.55% | 2.17B | |
+18.39% | 2.1B | |
-39.57% | 1.89B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- 1228 Stock